<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00338104</url>
  </required_header>
  <id_info>
    <org_study_id>0361-028</org_study_id>
    <nct_id>NCT00338104</nct_id>
  </id_info>
  <brief_title>Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin</brief_title>
  <official_title>Conversion of Hyperglycemic Patients Being Treated With Intravenous Insulin Infusions to Lantus Insulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the optimal dose of glargine insulin when
      converting from intravenous short-acting continuous insulin infusions in surgical and
      intensive care unit patients using a prospective, controlled, parallel group, randomized
      study design.

      Note: Lantus insulin is the proprietary name for glargine insulin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Critical illness causes an impairment of insulin secretion and insulin action, resulting in
      hyperglycemia even in normal individuals and a worsening of the hyperglycemia in patients
      with diabetes. Normalization of elevated glucose levels by intensive insulin infusion therapy
      in these critically ill patients has been proven to dramatically improve in-hospital
      mortality rates. After glucose levels have been controlled with insulin infusions, the best
      way to convert them to subcutaneous insulin regimens has not been demonstrated conclusively
      but the insulin regimen best suited is a combination of a basal insulin such as glargine
      (Lantus) insulin with premeal insulin boluses using a short-acting insulin such as Lispro or
      Aspart.

      Subjects will be randomized into three groups, 25 subjects in each group, the groups
      differing according to the starting dose of glargine insulin as follows:

        1. Multiply the total daily IV insulin dose, using the final 6 hour infusion rate to
           estimate the total daily dose, by 0.4 to get the starting dose of glargine, continuing
           the insulin drip for 5 hours after giving the glargine before stopping the infusion;

        2. Multiply the total daily IV insulin dose, using the final 6 hour infusion rate to
           estimate the total daily dose, by 0.6 to get the starting dose of glargine, continuing
           the insulin drip for 5 hours after giving the glargine before stopping the infusion;

        3. Multiply the total daily IV insulin dose, using the final 6 hour infusion rate to
           estimate the total daily dose, by 0.8 to get the starting dose of glargine, continuing
           the insulin drip for 5 hours after giving the glargine before stopping the infusion.

      The glargine insulin will then be continued as the basal insulin, adjusting doses every 24
      hours based on the fasting blood glucose level. In addition, patients will receive Lispro or
      Aspart insulin as prandial bolus insulins with the goals premeal being 80 - 120 mg/dl,
      including bedtime. Glucose measurements will be obtained every 1- 4 hours while patients are
      on their insulin infusions, depending upon the stability of their condition and the stability
      of their glucose levels. Following transfer to glargine insulin, they will have glucose
      measured at least four times per day, premeal and bedtime as per standard protocol in the
      hospital for patients receiving insulin. Glucose data will be obtained from such patients and
      this will be compared among the various glargine regimens.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Blood Glucose Values Between 80 - 140</measure>
    <time_frame>First 24 hours after conversion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Glucose Values &lt; 50 mg/dL</measure>
    <time_frame>First 24 hours after conversion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Glucose Levels &gt; 180 mg/dL</measure>
    <time_frame>First 24 hours after conversion</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Hyperglycemia</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>40% Glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a dose of glargine insulin equal to 40% of insulin drip rate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60% Glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a dose of glargine insulin equal to 60% of insulin drip rate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80% Glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a dose of glargine insulin equal to 80% of insulin drip rate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>Insulin glargine given at 40% of prior stable drip rate.</description>
    <arm_group_label>40% Glargine</arm_group_label>
    <other_name>Lantus is brand name for Glargine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>Insulin glargine given at 60% of prior stable drip rate.</description>
    <arm_group_label>60% Glargine</arm_group_label>
    <other_name>Lantus is brand name for Glargine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>insulin glargine</intervention_name>
    <description>Insulin glargine given at 80% of prior stable drip rate.</description>
    <arm_group_label>80% Glargine</arm_group_label>
    <other_name>Lantus is brand name for Glargine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fasting glucose &gt; 100 mg/dl

          -  Patients on surgical services or in intensive care units receiving intravenous insulin

        Exclusion Criteria:

          -  Inability to obtain informed consent from patient or next-of-kin

          -  Allergy to insulin

          -  Participation in another research study

          -  Patients for whom there are &quot;do-not-resuscitate&quot; orders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark E Molitch, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University Feinberg School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Schmeltz LR, DeSantis AJ, Schmidt K, O'Shea-Mahler E, Rhee C, Brandt S, Peterson S, Molitch ME. Conversion of intravenous insulin infusions to subcutaneously administered insulin glargine in patients with hyperglycemia. Endocr Pract. 2006 Nov-Dec;12(6):641-50.</citation>
    <PMID>17229660</PMID>
  </results_reference>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2006</study_first_submitted>
  <study_first_submitted_qc>June 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2006</study_first_posted>
  <results_first_submitted>December 1, 2008</results_first_submitted>
  <results_first_submitted_qc>April 3, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 6, 2009</results_first_posted>
  <last_update_submitted>April 3, 2009</last_update_submitted>
  <last_update_submitted_qc>April 3, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mark E. Molitch, M.D.</name_title>
    <organization>Northwestern University Feinberg School of Medicine</organization>
  </responsible_party>
  <keyword>insulin</keyword>
  <keyword>glargine</keyword>
  <keyword>intravenous</keyword>
  <keyword>subcutaneous</keyword>
  <keyword>hospital</keyword>
  <keyword>diabetes</keyword>
  <keyword>glucose</keyword>
  <keyword>inpatient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>75 patients with hyperglycemia were recruited from the inpatient service at Northwestern Memorial Hospital between August, 2004 and May, 2005.</recruitment_details>
      <pre_assignment_details>Patients had to be on a continuous insulin infusion to treat hyperglycemia prior to randomization</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>40% Group</title>
          <description>Glargine at 40% of insulin drip rate</description>
        </group>
        <group group_id="P2">
          <title>60% Group</title>
          <description>Glargine at 60% of insulin drip rate</description>
        </group>
        <group group_id="P3">
          <title>80% Group</title>
          <description>Glargine at 80% of insulin drip rate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>40% Group</title>
          <description>Glargine at 40% of insulin drip rate</description>
        </group>
        <group group_id="B2">
          <title>60% Group</title>
          <description>Glargine at 60% of insulin drip rate</description>
        </group>
        <group group_id="B3">
          <title>80% Group</title>
          <description>Glargine at 80% of insulin drip rate</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.4" spread="13.7"/>
                    <measurement group_id="B2" value="60.7" spread="10.8"/>
                    <measurement group_id="B3" value="58.6" spread="10.2"/>
                    <measurement group_id="B4" value="60.2" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.9" spread="5.0"/>
                    <measurement group_id="B2" value="30.6" spread="6.4"/>
                    <measurement group_id="B3" value="29.9" spread="8.0"/>
                    <measurement group_id="B4" value="29.8" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Blood Glucose Values Between 80 - 140</title>
        <description>Percentage of blood glucose values within the target range of eighty to one hundred forty mg per dL</description>
        <time_frame>First 24 hours after conversion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>40% Group</title>
            <description>Glargine at 40% of insulin drip rate</description>
          </group>
          <group group_id="O2">
            <title>60% Group</title>
            <description>Glargine at 60% of insulin drip rate</description>
          </group>
          <group group_id="O3">
            <title>80% Group</title>
            <description>Glargine at 80% of insulin drip rate</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Blood Glucose Values Between 80 - 140</title>
          <description>Percentage of blood glucose values within the target range of eighty to one hundred forty mg per dL</description>
          <units>percentage of blood glucose values</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Glucose Values &lt; 50 mg/dL</title>
        <description>Percentage of blood glucose values &lt; 50 mg/dL</description>
        <time_frame>First 24 hours after conversion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>40% Group</title>
            <description>Glargine at 40% of insulin drip rate</description>
          </group>
          <group group_id="O2">
            <title>60% Group</title>
            <description>Glargine at 60% of insulin drip rate</description>
          </group>
          <group group_id="O3">
            <title>80% Group</title>
            <description>Glargine at 80% of insulin drip rate</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Glucose Values &lt; 50 mg/dL</title>
          <description>Percentage of blood glucose values &lt; 50 mg/dL</description>
          <units>percentage of blood glucose values</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Glucose Levels &gt; 180 mg/dL</title>
        <description>Percentage of blood glucose levels &gt; 180 mg/dL</description>
        <time_frame>First 24 hours after conversion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>40% Group</title>
            <description>Glargine at 40% of insulin drip rate</description>
          </group>
          <group group_id="O2">
            <title>60% Group</title>
            <description>Glargine at 60% of insulin drip rate</description>
          </group>
          <group group_id="O3">
            <title>80% Group</title>
            <description>Glargine at 80% of insulin drip rate</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Glucose Levels &gt; 180 mg/dL</title>
          <description>Percentage of blood glucose levels &gt; 180 mg/dL</description>
          <units>percentage of blood glucose values</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>not all patients were analyzed in each group because insulin not given appropriately to those patients</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mark E. Molitch, M.D.</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312 503-4130</phone>
      <email>molitch@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

